Enrique Trilla

TL;DR: The lowest testosterone castration level with clinical relevance in medically castrated patients with prostate cancer was 32 ng/dl, and maximal androgen blockade provided a significantly longer survival free of androgen independent progression in those with breakthrough increases greater than 50 ng/DL.

TL;DR: The prevalence of osteoporosis seemed high in hormone-naive patients with prostate cancer, and it increased to more than 80% after 10 years ofADT, and clinicians should be aware of the impact of ADT on BMD to prevent bone mass loss.

TL;DR: Bone mineral density decreases during the first 24 months of androgen suppression with the most relevant effect occurring in the first year.

TL;DR: A small but clinically significant rate of patients under 3-month luteinizing hormone-releasing hormone agonist therapy fail to achieve or maintain castrate testosterone serum levels, which supports the need of monitoring testicular response during LH-RH agonists therapy.

TL;DR: Results show that the ability to achieve an undetectable nadir PSA and the time to reach it are the most significant predictors of the time of AIP in patients with locally advanced and metastatic prostate cancer under androgen suppression as a single therapy.